一种血管活性肠肽拮抗剂可区分脊髓细胞和淋巴细胞上的血管活性肠肽受体。

A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes.

作者信息

Gozes Y, Brenneman D E, Fridkin M, Asofsky R, Gozes I

机构信息

Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.

出版信息

Brain Res. 1991 Feb 1;540(1-2):319-21. doi: 10.1016/0006-8993(91)90528-4.

DOI:10.1016/0006-8993(91)90528-4

PMID:1647246

Abstract

Vasoactive intestinal peptide (VIP) is a neuropeptide which also interacts with cells of the immune system. The paucity of specific VIP receptor antagonists has hampered studies of possible receptor heterogeneity and of VIP function. To aid in achieving these goals, a new VIP antagonist, a hybrid between neurotensin and VIP, has been synthesized. This peptide interacted with VIP receptors on spinal cord cells with an affinity 10-fold greater than VIP itself. In contrast, 1000-fold higher concentrations of the antagonist were required to displace labeled VIP from its receptor on lymphoid cells as compared to VIP itself, suggesting VIP receptor heterogeneity between immune and spinal cord cells.

摘要

血管活性肠肽（VIP）是一种神经肽，它也与免疫系统的细胞相互作用。特异性VIP受体拮抗剂的缺乏阻碍了对可能的受体异质性和VIP功能的研究。为了有助于实现这些目标，一种新的VIP拮抗剂，即神经降压素和VIP的杂交体，已被合成。这种肽与脊髓细胞上的VIP受体相互作用，其亲和力比VIP本身高10倍。相比之下，与VIP本身相比，需要高1000倍的拮抗剂浓度才能将标记的VIP从其在淋巴细胞上的受体上置换下来，这表明免疫细胞和脊髓细胞之间存在VIP受体异质性。